

# Real-World Effectiveness of Perinatal RSV Immunoprophylaxis

NCT06172660

---

**Status** RECRUITING  
**Sponsor** Yale University  
**Enrollment** 3,750 participants

## Key Eligibility Criteria

---

### Inclusion (3)

- d 12months of age at the time of presentation for evaluation for an acute respiratory infection (ARI).
- Documentation of an ARI, which is defined as an acute onset ( $\leq 10$  days) illness that includes: At least two of the following symptoms: fever (measured or subjective), chills, rigors, myalgia, headache, sore throat, nausea or vomiting, diarrhea, fatigue, congestion OR any one of the following: cough, shortness of breath, difficulty breathing, olfactory disorder, taste disorder, confusion, persistent chest pain, pale, gray, hypoxia, clinical or radiographic evidence of pneumonia or respiratory distress syndrome.
- Residents of Connecticut

### Exclusion (6)

- Illness duration of  $> 10$  days at the time of respiratory specimen collection, measured from the date of the first symptom of the current acute illness.
- Parents/guardians are not able to provide informed consent
- To be eligible for inclusion in the study as a healthy control, an individual must meet all of the following criteria:
- Immunized against RSV d 12 months of age
- Residents of Connecticut
- ... and 1 more (see full listing online)

## Locations (1 total)

---

Yale Child Health Research Center, New Haven, Connecticut, United States